Can a common antioxidant rescue failing livers?

NCT ID NCT07765823

Recruiting now Disease control Sponsor: King Edward Medical University Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether adding N-acetylcysteine (NAC) to standard care improves survival in adults with acute liver failure not caused by acetaminophen. Sixty-two patients will be randomly assigned to receive NAC or standard care alone. The study tracks survival at 28 days, hospital stay length, and liver function changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-acetylcysteine (NAC), given orally or via nasogastric tube, alongside standard supportive care
What this could lead to: If NAC improves survival in this severe condition, it could become a standard add-on treatment for non-acetaminophen liver failure.
What could go wrong: This is a small, early-stage trial, and NAC may not show a clear benefit. The condition is complex, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute liver failure liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LIVER FAILURE NON-ACETAMINOPHINE INDUCED LIVER FAILURE

Contacts and locations

Locations

King Edward Medical University/Mayo Hospital Lahore
RECRUITING

Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.